Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc operates within a growing ADHD medication market, which has experienced a consistent annual growth rate of approximately 8% since 2010, culminating in total sales of around $18 billion in 2020. The company has also reported positive topline results from its CTx-1301 clinical trials, indicating a beneficial treatment effect compared to placebo, thereby enhancing its pipeline potential. This combination of market growth and favorable clinical data suggests a robust upside opportunity for Cingulate, factoring in both high risks and the potential for significant rewards.

Bears say

Cingulate Inc. reported a net loss of $4.8 million, translating to an earnings per share (EPS) of $(1.09), which was below both the company's estimates and analyst consensus. Additionally, previous losses reached $7.3 million, indicating a consistent trend of underperformance relative to expectations for EPS. Key risks impacting the company's financial outlook include liquidity concerns, potential failure of product candidates in clinical trials, regulatory hurdles, commercialization challenges, and unpredictable investor sentiment in the biotech sector.

Cingulate (CING) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Jan 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.